Engineering synthetic vaccines using cues from natural immunity.
about
Ex vivo cytosolic delivery of functional macromolecules to immune cellsImproving the clinical impact of biomaterials in cancer immunotherapy.Progress in material design for biomedical applicationsEngineering opportunities in cancer immunotherapyNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyCell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine Platformαβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapyA holistic approach to targeting disease with polymeric nanoparticlesMechanisms of HIV protein degradation into epitopes: implications for vaccine designForward Vaccinology: CTL Targeting Based upon Physical Detection of HLA-Bound PeptidesVascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigmCationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigensKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentSynthetic Nanoparticles for Vaccines and ImmunotherapyCarbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivoPoly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccineTowards programming immune tolerance through geometric manipulation of phosphatidylserine.Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccinationNanoparticle-based drug delivery to the vagina: a review.Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic.Nanoparticle approaches against bacterial infectionsBiomaterials for nanoparticle vaccine delivery systems.Hydrogels and scaffolds for immunomodulationPolymeric synthetic nanoparticles for the induction of antigen-specific immunological toleranceVaccine adjuvant materials for cancer immunotherapy and control of infectious diseaseOvercoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug deliverySpecifically targeted delivery of protein to phagocytic macrophages.Modulating antibacterial immunity via bacterial membrane-coated nanoparticlesNanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice.Whole-animal imaging and flow cytometric techniques for analysis of antigen-specific CD8+ T cell responses after nanoparticle vaccination.Supramolecular peptide vaccines: tuning adaptive immunity.Impact of molecular weight on the intrinsic immunogenic activity of poly(beta amino esters).Virus-like nanostructures for tuning immune response.Control of polymeric nanoparticle size to improve therapeutic delivery.Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancerModular Vaccine Design Using Carrier-Free Capsules Assembled from Polyionic Immune Signals.Cell membrane-camouflaged nanoparticles for drug delivery.
P2860
Q21131808-864C8278-1D2F-41F1-A510-59C537629FEAQ26766267-BF10DB52-BE87-4A83-BA8A-43990BB721C1Q26776367-FF2C0952-5FF9-4564-AAFF-C51E985C95A5Q26776373-AD6F8C04-C83F-46EE-8BC4-1E3207787901Q26782566-C6465A8B-478C-43C4-850D-08CF4FB3CC3EQ26784233-C277D393-EE30-48A8-8875-84A51167B518Q26861133-EBCB667E-F7BE-41B4-B93C-27D8DD62E9CEQ26865163-811DBE89-E46E-4BFD-8294-81CF0FB1E5D1Q26866505-352BF3F3-9399-43E8-B187-EEEA2BAE4987Q27008977-83E2DA66-E812-454A-8ED8-8A1B0107A6CEQ27026630-680B2181-7264-4788-AC46-50F56D313080Q27310007-CC220443-6461-48B4-9F7C-55CD0B5A342EQ28082880-6EEA0358-3700-493E-B9C6-22D8567FFAB6Q28085375-CC8EBAA9-C698-4382-9958-362A1ED4DF4BQ28388765-E6E9431D-22D3-43B3-9595-8FC4E75F733BQ30400146-AE37E65B-CA81-44B5-AAE1-5E8F0EBE7475Q30751004-36085284-0E68-44A6-81B6-04F4544AF287Q33746872-DCCC16F0-1DF9-4A80-81BB-5C4AD31EF642Q34074750-DDD59CC7-2103-4766-A68D-2854C355CA14Q34079533-A6001E7D-0F92-40B5-A9E5-70CF157DBABBQ34180316-9408C225-256B-48F5-A989-FCCDC7E6E430Q34339159-20C26B2F-B49D-4382-B5A9-10AD46A2A7BDQ34345012-79218297-E79F-4F0A-9E00-C62D4F81B45EQ34725541-F0E7410F-D605-4152-9081-D9E7C24343F7Q34985424-580DAAFF-EAE4-4091-90B7-F0EA707C4E68Q35035612-57D69C4F-9B2C-4299-9A50-D2298ABA42F8Q35134897-60F12611-466C-4871-BF3F-4EB5700C2357Q35168631-CCDEB688-E20C-4370-BCDE-FFA6C1BADC03Q35447934-DB29DEE8-79C1-417B-9E98-D967B26AD820Q35836140-A94CE0A8-2755-44DA-8D6E-9B8B015CC908Q35863346-AF27752A-9AAF-494F-A9CD-4C5183738F30Q35960520-6A8820B6-6674-49D3-BAE3-7C5377ED1F06Q35970758-4C2B174C-F868-4C86-9D07-1FC9228F9688Q36175673-57C2A5CF-FA6E-479B-B0C8-B8C64F83195EQ36225449-FF8C2B2C-EDA0-4697-AF0E-7BDFCC63107AQ36291687-6FC558A2-21F9-486F-97E7-5064A82BD02BQ36307555-CCA99B60-045C-4890-9D95-CB92EF779401Q36329068-8E32303E-458D-4DF2-A337-33F4AEDE9A5FQ36376261-47C2C895-3A7C-4CD2-A898-59DEADE90D45Q36396004-2D78EA66-64A8-4FF6-B38B-141579187C00
P2860
Engineering synthetic vaccines using cues from natural immunity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Engineering synthetic vaccines using cues from natural immunity.
@en
type
label
Engineering synthetic vaccines using cues from natural immunity.
@en
prefLabel
Engineering synthetic vaccines using cues from natural immunity.
@en
P2860
P356
P1433
P1476
Engineering synthetic vaccines using cues from natural immunity.
@en
P2093
Darrell J Irvine
Melody A Swartz
P2860
P2888
P304
P356
10.1038/NMAT3775
P407
P577
2013-11-01T00:00:00Z
P6179
1043856252